A Phase Ib/II study of ilixadencel in combination with checkpoint inhibitors (CPIs) for head & neck cancer, gastric adenocarcinoma and non-small cell lung cancer
Phase of Trial: Phase I/II
Latest Information Update: 23 Jul 2018
At a glance
- Drugs Ilixadencel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ILIAD
- Sponsors Immunicum
- 23 Jul 2018 According to an Immunicum media release, the US FDA has approved the clinical trial protocol for this Phase Ib/II trial. The trial protocol has been developed with guidance from EU regulatory authorities as well as from the FDA.
- 09 Apr 2018 New trial record
- 03 Apr 2018 According to an Immunicum media release, the Company plans to enroll the first patient during the second half of 2018.